Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies

Journal of Virology

Volumn 73, Issue 5, 1999, Pages 4009-4018

  Mascola, John R ^a,f   Lewis, Mark G ^a   Stiegler, Gabriela ^b   Harris, Dawn ^a   Vancott, Thomas C ^a   Hayes, Deborah ^a   Louder, Mark K ^a   Brown, Charles R ^c   Sapan, Christine V ^d   Frankel, Sarah S ^a   Lu, Yichen ^e   Robb, Merlin L ^a   Katinger, Hermann ^b   Birx, Deborah L ^a  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b UNIVERSITY OF AGRICULTURAL SCIENCES   (Austria)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NABI   (United States)

^e AVANT Immunotherapeutics Inc   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; HOST RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROVOCATION TEST; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINE PRODUCTION; VIRUS NEUTRALIZATION;

EID: 0032947286     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.5.4009-4018.1999     Document Type: Article

References (57)

1. Bahmatiyar, M., A. Fayaz, S. Nour-Salehi, M. Mohammadi, and H. Koprowski. 1976. Successful protection of humans exposed to rabies infection: postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 236:2751-2754.
2. Beasley, R. P., L. Y. Hwang, and C. E. Steven. 1983. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 3:135-141.
3. Casadevall, A., and M. D. Scharf. 1995. Return to the past: the case for antibody-based therapies in infectious diseases. J. Infect. Dis. 21:150-161.
4. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. J. Wu, C. R. Mackay, G. Larosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1996. The ß-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
5. Collman. R., J. W. Balliet, S. A. Gregory, H. Friedman, D. L. Kolson, N. Nathanson, and A. Srinivasan. 1992. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J. Virol. 66:7517-7521.
6. Conley, A. J., J. A, Kessler II, L. J. Boots, P. M. McKenna, W. A. Schleif, E. A. Emini, G. E. Mark III, H. Katinger, E. K. Cobb, S. M. Lunceford, S. R. Rouse, and K. K. Murthy. 1996. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70:6751-6758.
7. Doranz, B. J., J. Rucker, Y. J. Yi, R. J. Smyth, M. Samson, S. C. Peiper, M. Parmentier, R. G. Collman, and R. W. Doms. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the ß-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149-1158.
8. D'Souza, M. P., G. Milman, J. A. Bradac, D. McPhee, C. V. Hanson, R. M. Hendry, T. Corcoran, J. Stott, M. Fung, C. Hanson, J. Laman, J. Mascola, S. Rasheed, D. Richman, H. Schuilemaker, C. Thiriart, M. Wainberg, J. Weber, S. Beddows, S. Tilley, J. Robinson, S. Zolla-Pazner, and H. Katinger. 1995. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 9:867-874.
9. Eichberg, J. W., K. K. Murthy, R. H. R. Ward, and A. M. Prince. 1992. Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG. AIDS Res. Hum. Retroviruses 8:1515.
10. Emini, E. A., W. A. Schleif, J. H. Nunberg, A. J. Conley, Y. Eda, S. Tokiyoshi, S. D. Putney, S. Matsushita, K. E. Cobb, C. M. Jett, J. W. Eichberg, and K. K. Murthy. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-730.
11. Gardner, M., A. Rosenthal, M. Jennings, J. Yee, L. Antipa, and J. Robinson. 1995. Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res. Hum. Retroviruses 11:843-854.
12. Gauduin, M. C., P. W. H. I. Parren, R. Weir, C. F. Barbas, D. R. Burton, and R. A. Koup. 1997. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3:1389-1393.
13. Gellis, S. S., A C. McGuinnes, and M. Peters. 1945. Study of prevention of mumps orchitis by gamma globulin. Am. J. Med. Sci. 210:661-664.
14. Groothius, J. R., E. A. F. Simoes, M. J. Levin, C. B. Hall, C. E. Long, W. J. Rodriguez, J. Arrobio, H. C. Meissner, D. R. Fulton, R. C. Welliver, D. A. Tristram, G. R. Siber, G. A. Prince, M. Van Raden, and V. G. Hemming. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N. Engl. J. Med. 329:1524-1530.
15. Haigwood, N. L., A. Watson, W. F. Sutton, J. McClure, A Lewis, J. Ranchalis, B. Travis, G. Voss, N. L. Letvin, S. L. Hu, V. M. Hirsch, and P. R. Johnson. 1996. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol. Lett. 51:107-114.
16. Hammon, W. M., L. L. Coriel, and P. F. Wehrle. 1953. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. JAMA 151:1272-1285.
17. Hasenkrug, K. J., and B. Chesebro. 1997. Immunity to retroviral infection: the Friend virus model. Proc. Natl. Acad. Sci. USA 94:7811-7816.
18. Hohdatsu. T., R. Pu, B. A. Torres, S. Trujillo, M. B. Gardner, and J. K. Yamamoto. 1993. Passive antibody protection of cats against feline immunodeficiency virus infection. J. Virol. 67:2344-2348.
19. Janeway, C. A. 1945. Use of concentrated human serum gamma-globulin in the prevention and treatment of measles. Bull. N. Y. Acad. Med. 21:202-220.
20. Kim, F. M., D. L. Kolson, J. W. Balliet, A. Srinivasan, and R. G. Collman. 1995. V3-independent determinants of macrophage tropism in a primary human immunodeficiency virus type 1 isolate. J. Virol. 69:1755-1761.
21. Korns, R. F. 1952. Prevention of german measles with immune serum globulin. J. Infect. Dis. 90:183-189.
22. Lambert, J. S., L. M. Mofenson, C. V. Fletcher, J. Moye, Jr., E. R. Stiehm, W. A. Meyer III, G. J. Nemo, B. J. Mathieson, G. Hirsch, C. V. Sapan, L. M. Cummins, E. Jimenez, E. O'neil, A. Kovacs, and A. Stek. 1997. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infecled pregnant women and their newborns. J. Infect. Dis. 175:283-291.
23. Lewis, M. G., S. Bellah, K. McKinnon, J. Yalley-Ogunro, P. M. Zack, W. R. Elkins, R. C. Desrosiers, and G. A. Eddy. 1994. Titration and characterization of two rhesus-derived SlVmac challenge stocks. AIDS Res. Hum. Retroviruses 10:213-220.
24. Lewis, M. G., W. R. Elkins, F. E. McCutchan, R. E. Benveniste, C. Y. Lai, D. C. Montefiori, D. S. Burke, G. A. Eddy, and A. Shafferman. 1993. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine 11:1347-1355.
25. Lewis, M. G., J. Yalley-Ogunro, J. J. Greenhouse, T. P. Brennan, J. Bo Hiang, T. C. VanCott, Y. Lu, G. A. Eddy, and D. L. Birx. 1999. Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus. J. Virol. 73:1262-1270.
26. Li, J., C. I. Lord, W. Haseltine, N. L. Letvin, and J. Sodroski. 1992. Infection of cynomolgus monkeys with a chimeric HIV-1/SIV virus that expresses the HlV-1 envelope glycoproteins. J. Acquired Immune Defic. Syndr. 5:639-646.
27. Lifson, J. D., M. A. Nowak, S. Goldstein, J. L. Rossio, A. Kinter, G. Vasquez. T. A. Wiltrout, C. Brown, D. Schneider, L. Wahl, A. L. Lloyd, J. Williams, W. R. Elkins, A. S. Fauci, and V. M. Hirsch. 1997. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J. Virol. 71:9508-9514.
28. Lu, Y. C., C. D. Pauza, X. S. Lu, D. C. Monlefiori, and C. J. Miller. 1998. Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 19:6-18.
29. Luciw, P. A., E. Pratt-Lowe, K. E. S. Shaw, J. A. Levy, and C. Cheng-Mayer. 1995. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc. Natl. Acad. Sci. USA 92:7490-7494.
30. Mascola, J. R., M. K. Louder, T. C. VanCott, C. V. Sapan, J. S. Lambert, L. R. Muenz, B. Bunow, D. L. Birx, and M. L. Robb. 1997. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71:7198-7206.
31. Mascola, J. R., J. Louwagie, F. E. McCutchan, C. L. Fischer, P. A. Hegerich, K. F. Wagner, A. K. Fowler, J. G. McNeil, and D. S. Burke, 1994. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J. Infect. Dis. 169:48-54.
32. Mascola, J. R., S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, M. C. Keefer, M. J. McElrath, M. C. Walker, K. F. Wagner, J. G. McNeil, F. E. McCutchan, and D. S. Burke. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340-348.
33. Matthews, T. J. 1994. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res. Hum. Retroviruses 10:631-632.
34. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Rüker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
35. Pincus, S. H., R. Cole, R. Ireland, F. McAtee, R. Fujisawa, and J. Portis. 1995. Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. J. Virol. 69:7152-7158.
36. Prince, A. M., H. Reesink, D. Pascual, B. Horowitz, I. Hewlett, K. K. Murthy, K. E. Cobb, and J. W. Eichberg. 1991. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res. Hum. Retroviruses 7:971-973.
37. sm infection by passive immunization in cynomolgus monkeys. Nature 352:436-438.
38. Ranjbar, S., S. Jones, E. J. Stott, and N. Almond. 1997. The construction and evaluation of SIV/HIV chimeras that express the envelope of European HIV type 1 isolates. AIDS Res. Hum. Retroviruses 13:797-800.
39. Reimann, K. A., J. T. Li, R. Veazey, M. Halloran, I. W. Park, G. B. Karlsson, J. Sodroski, and N. L. Letvin. 1996. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70:6922-6928.
40. Reimann, K. A, J. T. Li, G. Voss, C. Lekutis, K. Tenner-Racz, P. Racz, W. Y. Lin, D. C. Montefiori, D. E. Lee-Parritz, Y. C. Lu, R. G. Collman, J. Sodroski, and N. L, Letvin. 1996. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian human immunodeficiency virus in rhesus monkeys. J. Virol. 70:3198-3206.
41. Robbins, J. B., R. Schneerson, and S. C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387-1398.
42. Rosenberg, Y. J., P. M. Zack, E. C. Leon, B. D. White, S. F. Papermaster, E. Hall, J. J. Greenhouse, G. A. Eddy, and M. G. Lewis. 1994. Immunological and virotogical changes associated with decline in CD4/CD8 ratios in lymphoid organs of SIV-infected macaques. AIDS Res. Hum. Retroviruses 10:863-872.
43. Ross, A. H. 1962. Modification of chicken pox in family contacts by administration of gamma globulin. N. Engl. J. Med. 267:369-376.
44. Sakuragi, S., R. Shibata, R. Mukai, T. Komatzu, M. Fukasawa, H. Sakai, J.-I. Sakuragi, M. Kawamura, K. Ibuki, M. Hayami, and A. Adachi. 1992. Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus. J. Gen. Virol. 73:2983-2987.
45. Shibata, R., M. Kawamura, H. Sakai, M. Hayami, A. Ishimoto, and A. Adachi. 1991. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J. Virol. 65:3514-3520.
46. Shibata, R., F. Maldarelli, C. Siemon, T. Matano, M. Parta, G. Miller, T. Fredrickson, and M. A. Martin. 1997. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J. Infect. Dis. 176:362-373.
47. Smyth, R. J., Y. J. Yi, A. Singh, and R. G. Collman. 1998. Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate. J. Virol. 72:4478-4484.
48. Snydman, D. R., B. G. Werner, B. Heinze-Lacey, V. P. Berardi, N. L. Tilney, R. L. Kirkman, E. L. Milford, S. I. Cho, H. L. Bush, Jr., and A. S. Levey. 1987. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 317:1049-1054.
49. +-B-cell changes predict rapid disease progression after simian-human immunodeficiency virus infection in macaques. J. Virol. 72:1600-1605.
50. Stokes, J., Jr., and J. R. Neefe. 1945. The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 127:144-145.
51. Trkola, A., A. B. Pomales, H. Yuan, B. Korber, P. J. Madden, G. P. Allaway, H. Katinger, C. F. Barbas III. D. R. Burton, D. D. Ho, and J. P. Moore. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
52. Trkola, A., M. Purtscher, T. Muster, C. Balaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70: 1100-1108.
53. Vahey, M. T, and M. T. Wong. 1995. Quantitative liquid hybridization PCR method employing storage phosphor technology, p. 313-338. In C. W. Dieffenback and G. S. Dveksler (ed.), PCR primer: a laboratory manual. Cold Spring Harbor Laboratory Press, Plainview, N.Y.
54. VanCott, T. C., R. W. Kaminski, J. R. Mascola, V. S. Kalyanaraman, N. M. Wassef, C. R. Alving, J. T. Ulrich, G. H. Lowell, and D. L. Birx. 1998. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J. Immunol. 160:2000-2012.
55. Van Rompay, K. K. A., C. J. Berardi, S. Dillard-Telm, R. P. Tarara, D. R. Canfield, C. R. Valverde, D. C. Montefiori, K. S. Cole, R. C. Montelaro, C. J. Miller, and M. L. Marthas. 1998. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis. 177:1247-1259.
56. Wong, M. T., M. J. Dolan, E. Kozlow, R. Doe, G. P. Melcher, D. S. Burke, R. N. Boswell, and M. Vahey. 1996. Patterns of virus burden and T cell phenotype are established early and are correlated with the rate of disease progression in human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 173:877-887.
57. Wrin, T., T. P. Loh, J. C. Vennari, H. Schuitemaker, and J. H. Nunberg. 1995. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccinee sera. J. Virol. 69:39-48.